Academic Journal
Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus
| العنوان: | Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus |
|---|---|
| المؤلفون: | Lamrayah, Myriam, Charriaud, Fanny, Desmares, Manon, Coiffier, Céline, Megy, Simon, Colomb, Evelyne, Terreux, Raphaël, Lucifora, Julie, Durantel, David, Verrier, Bernard |
| المساهمون: | Laboratoire de Biologie Tissulaire et d'ingénierie Thérapeutique (LBTI), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Interactions entre HBV, HDV, et des facteurs hépatiques de l'hôte CIRI (CIRI-HepVIR), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon), Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie et chimie des protéines Lyon (IBCP), ANR-11-EQPX-0035,PHENOCAN,Phenotypage pour le cancer(2011) |
| المصدر: | ISSN: 0166-3542 ; Antiviral Research ; https://hal.science/hal-03923266 ; Antiviral Research, 2023, 209, pp.105483. ⟨10.1016/j.antiviral.2022.105483⟩. |
| بيانات النشر: | CCSD Elsevier Masson |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Hepatitis B virus, neutralizing antibodies, PreS1 peptide, TLR agonist, nanoparticle, poly(lactic acid), [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology |
| الوصف: | International audience ; Hepatitis B virus remains a major medical burden with more than 250 million chronically infected patients worldwide and 900,000 deaths each year, due to the disease progression towards severe complications (cirrhosis, hepatocellular carcinoma). Despite the availability of a prophylactic vaccine, this infection is still pandemic in Western Pacific and African regions, where around 6% of the adult population is infected. Among novel anti-HBV strategies, innovative drug delivery systems, such as nanoparticle platforms to deliver vaccine antigens or therapeutic molecules have been investigated. Here, we developed polylactic acid-based biodegradable nanoparticles as an innovative and efficient vaccine. They are twice functionalized by (i) the entrapment of Pam3CSK4, an immunomodulator and ligand to Toll-Like-Receptor 1/2, and by (ii) the adsorption/coating of myristoylated (2–48) derived PreS1 from the HBV surface antigen, identified as the major viral attachment site on hepatocytes. We demonstrate that such formulations mimic HBV virion with an efficient peptide recognition by the immune system, and elicit potent and durable antibody responses in naive mice during at least one year. We also show that the most efficient in vitro viral neutralization was observed with NP-Pam3CSK4-dPreS1 sera. The immunogenicity of the derived HBV antigen is modulated by the likely synergistic action of both the dPreS1 coated nanovector and the adjuvant moiety. This formulation represents a promising vaccine alternative to fight HBV infection. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.antiviral.2022.105483 |
| الاتاحة: | https://hal.science/hal-03923266 https://hal.science/hal-03923266v1/document https://hal.science/hal-03923266v1/file/2023%20-%20Lamarayat%20et%20al%20-%20AVR%20-%20for%20HAL.pdf https://doi.org/10.1016/j.antiviral.2022.105483 |
| Rights: | info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.55354585 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.antiviral.2022.105483 |
|---|